265 related articles for article (PubMed ID: 23997103)
1. Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat.
Pankey EA; Thammasiboon S; Lasker GF; Baber S; Lasky JA; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2013 Nov; 305(9):H1288-96. PubMed ID: 23997103
[TBL] [Abstract][Full Text] [Related]
2. Analysis of responses to the Rho-kinase inhibitor Y-27632 in the pulmonary and systemic vascular bed of the rat.
Casey DB; Badejo AM; Dhaliwal JS; Sikora JL; Fokin A; Golwala NH; Greco AJ; Murthy SN; Nossaman BD; Hyman AL; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2010 Jul; 299(1):H184-92. PubMed ID: 20435851
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats.
Abe K; Toba M; Alzoubi A; Koubsky K; Ito M; Ota H; Gairhe S; Gerthoffer WT; Fagan KA; McMurtry IF; Oka M
Am J Respir Cell Mol Biol; 2011 Oct; 45(4):804-8. PubMed ID: 21378262
[TBL] [Abstract][Full Text] [Related]
4. Role of Src tyrosine kinases in experimental pulmonary hypertension.
Pullamsetti SS; Berghausen EM; Dabral S; Tretyn A; Butrous E; Savai R; Butrous G; Dahal BK; Brandes RP; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Rosenkranz S; Schermuly RT
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1354-65. PubMed ID: 22516066
[TBL] [Abstract][Full Text] [Related]
5. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
[TBL] [Abstract][Full Text] [Related]
6. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
7. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
Jasińska-Stroschein M; Owczarek J; Plichta P; Orszulak-Michalak D
Pharmacology; 2014; 93(3-4):145-50. PubMed ID: 24662671
[TBL] [Abstract][Full Text] [Related]
8. Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension.
Akagi S; Nakamura K; Miura D; Saito Y; Matsubara H; Ogawa A; Matoba T; Egashira K; Ito H
Int Heart J; 2015 May; 56(3):354-9. PubMed ID: 25902888
[TBL] [Abstract][Full Text] [Related]
9. The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat.
Pankey EA; Byun RJ; Smith WB; Bhartiya M; Bueno FR; Badejo AM; Stasch JP; Murthy SN; Nossaman BD; Kadowitz PJ
Can J Physiol Pharmacol; 2012 Jul; 90(7):825-35. PubMed ID: 22591047
[TBL] [Abstract][Full Text] [Related]
10. Calorie Restriction Attenuates Monocrotaline-induced Pulmonary Arterial Hypertension in Rats.
Ding M; Lei J; Qu Y; Zhang H; Xin W; Ma F; Liu S; Li Z; Jin F; Fu E
J Cardiovasc Pharmacol; 2015 Jun; 65(6):562-70. PubMed ID: 25636073
[TBL] [Abstract][Full Text] [Related]
11. Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat.
Badejo AM; Dhaliwal JS; Casey DB; Gallen TB; Greco AJ; Kadowitz PJ
Am J Physiol Lung Cell Mol Physiol; 2008 Nov; 295(5):L828-36. PubMed ID: 18689606
[TBL] [Abstract][Full Text] [Related]
12. Analysis of erectile responses to imatinib in the rat.
Pankey EA; Lasker GF; Gur S; Hellstrom WJ; Kadowitz PJ
Urology; 2013 Jul; 82(1):253.e17-24. PubMed ID: 23806406
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.
Pankey EA; Bhartiya M; Badejo AM; Haider U; Stasch JP; Murthy SN; Nossaman BD; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2011 Mar; 300(3):H792-802. PubMed ID: 21217076
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1α depletion or imatinib treatment.
Veith C; Zakrzewicz D; Dahal BK; Bálint Z; Murmann K; Wygrecka M; Seeger W; Schermuly RT; Weissmann N; Kwapiszewska G
Thromb Haemost; 2014 Dec; 112(6):1288-303. PubMed ID: 25231004
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat.
Jasińska-Stroschein M; Owczarek J; Wesołowska A; Orszulak-Michalak D
Acta Pharm; 2014 Sep; 64(3):345-53. PubMed ID: 25296680
[TBL] [Abstract][Full Text] [Related]
16. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Leong ZP; Okida A; Higuchi M; Yamano Y; Hikasa Y
Vascul Pharmacol; 2018 Jan; 100():41-50. PubMed ID: 29100963
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Li XL; Guan RJ; Li JJ
J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
[TBL] [Abstract][Full Text] [Related]
18. Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension.
Yang J; Li X; Al-Lamki RS; Wu C; Weiss A; Berk J; Schermuly RT; Morrell NW
Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):34-42. PubMed ID: 23139294
[TBL] [Abstract][Full Text] [Related]
19. Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat.
Cotroneo E; Ashek A; Wang L; Wharton J; Dubois O; Bozorgi S; Busbridge M; Alavian KN; Wilkins MR; Zhao L
Circ Res; 2015 May; 116(10):1680-90. PubMed ID: 25767292
[TBL] [Abstract][Full Text] [Related]
20. Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor.
Dhaliwal JS; Badejo AM; Casey DB; Murthy SN; Kadowitz PJ
J Pharmacol Exp Ther; 2009 Jul; 330(1):334-41. PubMed ID: 19369577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
